{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:17:26Z","timestamp":1740122246156,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Huntsman Cancer Institute Neurologic Disease Center"},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["P30CA42014","P30CA42014","P30CA42014"],"award-info":[{"award-number":["P30CA42014","P30CA42014","P30CA42014"]}]},{"DOI":"10.13039\/100010637","name":"Huntsman Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11060-022-04064-x","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:02:38Z","timestamp":1656442958000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost\u2013benefit analysis"],"prefix":"10.1007","volume":"159","author":[{"given":"Savannah","family":"Gelhard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amiee","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Colman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-8658","authenticated-orcid":false,"given":"Joe S.","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"4064_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H et al (2018) The elderly left behind-changes in survival trends of primary central nervous system Lymphoma over the past 4 decades. Neuro Oncol 20:687\u2013694. https:\/\/doi.org\/10.1093\/neuonc\/nox187","journal-title":"Neuro Oncol"},{"key":"4064_CR2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS Lymphoma. J Clin Oncol 35:2410\u20132418. https:\/\/doi.org\/10.1200\/JCO.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"4064_CR3","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","volume":"122","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Gupta NK, Mannis GN et al (2013) How I treat CNS Lymphomas. Blood 122:2318\u20132330. https:\/\/doi.org\/10.1182\/blood-2013-06-453084","journal-title":"Blood"},{"key":"4064_CR4","first-page":"2013","volume":"35","author":"N Templates","year":"2014","unstructured":"Templates N (2014) Primary CNS Lymphoma rituximab primary CNS Lymphoma. J Clin Oncol 35:2013\u20132014","journal-title":"J Clin Oncol"},{"key":"4064_CR5","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS Lymphoma: the next step. J Clin Oncol 18:3144\u20133150. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3144","journal-title":"J Clin Oncol"},{"key":"4064_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.10.1595","author":"AMP Omuro","year":"2005","unstructured":"Omuro AMP, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system Lymphoma. Arch Neurol. https:\/\/doi.org\/10.1001\/archneur.62.10.1595","journal-title":"Arch Neurol"},{"key":"4064_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS Lymphoma. Blood 125:1403\u20131410. https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"key":"4064_CR8","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL et al (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS Lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061\u20133068. https:\/\/doi.org\/10.1200\/JCO.2012.46.9957","journal-title":"J Clin Oncol"},{"key":"4064_CR9","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2021.39.15_suppl.7506","volume":"39","author":"T Batchelor","year":"2021","unstructured":"Batchelor T, Giri S, Ruppert AS et al (2021) Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system Lymphoma: results of CALGB 51101 (Alliance). J Clin Oncol 39:7506\u20137506. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.7506","journal-title":"J Clin Oncol"},{"key":"4064_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","volume":"16","author":"E Schorb","year":"2016","unstructured":"Schorb E, Finke J, Ferreri AJM et al (2016) High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS Lymphoma\u2014a randomized phase III trial (MATRix). BMC Cancer 16:282. https:\/\/doi.org\/10.1186\/s12885-016-2311-4","journal-title":"BMC Cancer"},{"key":"4064_CR11","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L. Lancet Haematol 4:e510\u2013e523. https:\/\/doi.org\/10.1016\/S2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"4064_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS Lymphoma in patients 60\u00a0years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/JCO.18.00306","journal-title":"J Clin Oncol"},{"key":"4064_CR13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/neuonc\/nou057","volume":"16","author":"A Prica","year":"2014","unstructured":"Prica A, Chan K, Cheung M (2014) Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system Lymphoma: a cost-effectiveness analysis. Neuro Oncol 16:1384\u20131391. https:\/\/doi.org\/10.1093\/neuonc\/nou057","journal-title":"Neuro Oncol"},{"key":"4064_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/10428194.2020.1711902","volume":"61","author":"JM Beca","year":"2020","unstructured":"Beca JM, Raza K, Mow E et al (2020) Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system Lymphoma. Leuk Lymphoma 61:1097\u20131107. https:\/\/doi.org\/10.1080\/10428194.2020.1711902","journal-title":"Leuk Lymphoma"},{"key":"4064_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/amiajnl-2013-002511","volume":"22","author":"K Kawamoto","year":"2015","unstructured":"Kawamoto K, Martin CJ, Williams K et al (2015) Value driven outcomes (VDO): a pragmatic, modular, and extensible software framework for understanding and improving health care costs and outcomes. J Am Med Inform Assoc 22:223\u2013235. https:\/\/doi.org\/10.1136\/amiajnl-2013-002511","journal-title":"J Am Med Inform Assoc"},{"key":"4064_CR16","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system Lymphoma: the memorial sloan-kettering cancer center prognostic model. J Clin Oncol 24:5711\u20135715. https:\/\/doi.org\/10.1200\/JCO.2006.08.2941","journal-title":"J Clin Oncol"},{"key":"4064_CR17","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"LE Schnipper","year":"2016","unstructured":"Schnipper LE, Davidson NE, Wollins DS et al (2016) Updating the american society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34:2925\u20132934. https:\/\/doi.org\/10.1200\/JCO.2016.68.2518","journal-title":"J Clin Oncol"},{"key":"4064_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2016.12226","volume":"316","author":"VS Lee","year":"2016","unstructured":"Lee VS, Kawamoto K, Hess R et al (2016) Implementation of a value-driven outcomes program to identify high variability in clinical costs and outcomes and association with reduced cost and improved quality. JAMA 316:1061. https:\/\/doi.org\/10.1001\/jama.2016.12226","journal-title":"JAMA"},{"key":"4064_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1182\/blood-2019-132121","volume":"134","author":"L Jafari","year":"2019","unstructured":"Jafari L, Hussain J, Krishnadasan R et al (2019) Implementation of outpatient high-dose cytarabine (HiDAC) for AML: evaluation of the impact of transitioned outpatient chemotherapy in an oncology care model setting. Blood 134:2153\u20132153. https:\/\/doi.org\/10.1182\/blood-2019-132121","journal-title":"Blood"},{"key":"4064_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/bmt.2017.23","volume":"52","author":"E Schorb","year":"2017","unstructured":"Schorb E, Fox CP, Fritsch K et al (2017) High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant 52:1113\u20131119. https:\/\/doi.org\/10.1038\/bmt.2017.23","journal-title":"Bone Marrow Transplant"},{"key":"4064_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbmt.2016.09.024","volume":"23","author":"M Scordo","year":"2017","unstructured":"Scordo M, Bhatt V, Hsu M et al (2017) A comprehensive assessment of toxicities in patients with central nervous system Lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning. Biol Blood Marrow Transpl 23:38\u201343. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.024","journal-title":"Biol Blood Marrow Transpl"},{"key":"4064_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.7326\/0003-4819-118-3-199302010-00011","volume":"118","author":"MC Creditor","year":"1993","unstructured":"Creditor MC (1993) Hazards of hospitalization of the elderly. Ann Intern Med 118:219. https:\/\/doi.org\/10.7326\/0003-4819-118-3-199302010-00011","journal-title":"Ann Intern Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04064-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T10:10:53Z","timestamp":1661767853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04064-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4064"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04064-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a retrospective observational study. The University of Utah IRB approved this study with a waiver of informed consent as protocol #66337.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Exemption to informed consent was obtained through IRB approval for this retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Exemption to informed consent was obtained through IRB approval for this retrospective study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}